---
created: 2025-04-13
updated: 2025-04-13T10:53
id: EVCl$WIMmw
specialty: pharmaco
specialty_id: 331
tags:
  - source/ak-original-decks::step-1::zanki-pharmacology
  - "source/ak-step1-v11:": 
  - theme/firstaid::10-hematology-oncology::05-pharm::22-ruxolitinib
  - "source/ak-step1-v11:": 
  - theme/ome::13-hematology-oncology::04-proliferation::02-myeloproliferation
  - "source/ak-step1-v11:": 
  - source/ome-banner::basic-science::13-hematology-oncology::18-myeloproliferative-disorders
  - "source/ak-step1-v11:": 
  - theme/physeo::11-pathology::10-hemeonc-pathology::14-myeloproliferative-disorders
  - "source/ak-step1-v11:": 
  - theme/sketchypath::10-myeloid-&-lymphoid::01-myeloid-disorders::01-myeloproliferative-neoplasms-&-myelodysplastic-syndromes
  - "source/ak-step1-v11:": 
  - theme/sketchypharm::08-antineoplastics::smallmoleculeinhibitors(tyrosinekinase-proteasomeinhibitors-cdkinhibitors)
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::8000-8999::8540
  - source/ak-step1-v11::^other::^expn
  - source/ak-step1-v11::^other::^highyield::2-relativelyhighyield"
type: flashcard
---

# Question
Ruxolitinib is used to treat chronic myeloproliferative disorders that have **JAK2::non-receptor tyrosine kinase** mutations including **myelofibrosis** and **polycythemia vera**

---

# Answer
ddx = CML; primary myelofibrosis will present also with hepatosplenomegaly, not only splenomegaly    Because these target the proliferation of myeloid cells, myelosuppression is a side effect